The stakes of this work are considerable. Leishmaniasis and Chagas disease, caused by trypanosomatid parasites transmitted by sand flies and triatomine bugs respectively, affect millions of people across more than 90 countries, with Brazil among the six most burdened nations. According to the Pan American Health Organization, an estimated 6 to 7 million people are infected with Chagas disease worldwide, with roughly 30,000 new cases and 14,000 deaths each year. Leishmaniasis manifests in clinical forms ranging from disfiguring cutaneous lesions to fatal visceral disease, while chronic Chagas cardiomyopathy can silently progress to heart failure and sudden death decades after the initial infection.

Current therapies fall far short of what clinicians need. Pentavalent antimonials, amphotericin B, miltefosine, benznidazole, and nifurtimox all suffer from significant toxicity, lengthy treatment regimens, variable efficacy depending on disease stage, and rising resistance. This therapeutic gap motivated the research team, led by scientists at the State University of Maringá in Brazil, to screen a panel of four synthetic azobenzenoid compounds—PH011669, S981796, L170224, and CaCS2—against multiple life stages of both parasites using a combination of laboratory and computational approaches.

The in vitro results revealed a striking hierarchy of activity. While PH011669 and S981796 showed no meaningful effect on proliferating promastigotes or epimastigotes, both displayed potent activity against intracellular amastigotes of L. amazonensis, the clinically relevant stage that hides inside host macrophages, with half-inhibitory concentrations below 10 micromolar and selectivity indices exceeding 44. L170224 showed a narrower profile, active against Leishmania but inert against T. cruzi. Only CaCS2 demonstrated broad-spectrum activity across every stage tested: promastigotes and amastigotes of L. amazonensis, and both epimastigotes and bloodstream trypomastigotes of T. cruzi, with inhibitory concentrations ranging from roughly 9 to 22 micromolar.

Just as important as potency was safety. CaCS2 showed remarkably low toxicity toward mammalian cells, with half-cytotoxic concentrations of 428 micromolar against J774A.1 macrophages and 673.5 micromolar against LLC-MK2 epithelial cells, yielding selectivity indices between 30 and 60 depending on the parasite stage. By comparison, the reference drugs miltefosine and benznidazole, though potent in some assays, displayed substantially lower selectivity margins. This favorable therapeutic window prompted the team to focus all subsequent mechanistic work on CaCS2 alone.

The mystery deepened when the researchers considered the compound’s history. CaCS2 was previously identified as an inhibitor of chorismate synthase, an enzyme found in fungi, mycobacteria, plants, and apicomplexan parasites—but not in trypanosomatids. Since T. cruzi and Leishmania lack the chorismate synthase gene entirely, the observed antiparasitic activity could not be explained by the compound’s known mechanism. Something else inside these parasites had to be the target.

To find it, the team turned to a reverse screening strategy called the Similarity Ensemble Approach, which compares the chemical structure of a query molecule against the known ligands of thousands of annotated proteins. The analysis flagged RNA editing ligase 1, or REL1, as a high-confidence candidate, with a statistical significance value of 1.76 × 10⁻¹². REL1 is a compelling target for several reasons: it is indispensable for the uridine insertion and deletion reactions that edit mitochondrial mRNA in trypanosomatids, it cannot be functionally replaced by its partner enzyme REL2, and it has no close homolog in mammalian cells, minimizing the risk of host toxicity.

Using AlphaFold-predicted structures of REL1 from both L. braziliensis and T. cruzi, superimposed onto the crystal structure of the T. brucei enzyme bound to ATP and magnesium, the researchers mapped the enzyme’s binding cavities. Blind docking across 100 simulations revealed that CaCS2 preferentially occupied two pockets: the orthosteric site, where the ATP cofactor normally binds, and an alternative cavity on the opposite face of the protein. Guided docking with three independent programs—AutoDock Vina, AutoDock 4.2.3, and Molegro—consistently ranked CaCS2’s binding at the orthosteric site second only to ATP itself, with the ligand forming hydrogen bonds and electrostatic contacts with key catalytic residues such as Lys42, Arg63, and Phe162 in the Leishmania enzyme, and Ile55, Lys81, and Phe203 in the Trypanosoma version.

Molecular dynamics simulations running 100 nanoseconds for each protein-ligand complex provided the decisive test. The systems reached equilibrium after about 40 nanoseconds, and CaCS2 bound at the orthosteric site remained stably anchored throughout the simulation in both parasite enzymes, mirroring the behavior of ATP. In contrast, the ligand at the alternative site proved transient: it diffused away from the pocket early in the Leishmania simulation, and in the Trypanosoma system it detached before returning after 35 nanoseconds. Analyses of the radius of gyration and per-residue fluctuations confirmed that the protein never unfolded in any complex, and contact-frequency calculations showed that CaCS2 at the orthosteric site shared nine key residues with ATP in both species—far more than the six or seven residues engaged at the alternative site.

Taken together, the evidence suggests that CaCS2 inhibits REL1 by competing with ATP at the catalytic site rather than by acting as an allosteric effector, a conclusion consistent with the compound’s negative net charge, which resembles the charged phosphate backbone that anchors ATP in the pocket. The authors caution that direct enzyme inhibition assays will be needed to confirm the mechanism, but the convergence of broad-spectrum antiparasitic activity, low mammalian cytotoxicity, and stable predicted binding to a parasite-essential, human-absent enzyme makes CaCS2 a promising lead scaffold. As drug resistance continues to erode the value of existing therapies for Chagas disease and leishmaniasis, molecules that exploit the unique biochemistry of RNA editing may offer a much-needed path forward.

Subject of Research: Azobenzenoid derivatives as inhibitors of RNA editing ligase 1 in Trypanosoma cruzi and Leishmania amazonensis parasites

Article Title: Integrated Experimental and Computational Investigation of Azobenzenoid Derivatives Against Trypanosomatid: RNA Editing Ligase 1 as a Potential Molecular Target

Article References: Khan, A., Balbinot, R. B., Lazarin-Bidóia, D., Paetzold, M. G., Seixas, Í. N., Ramos Silva, G. N., Fernandez, M. A., Nakamura, C. V., & Seixas, F. A. V. (2026). Integrated Experimental and Computational Investigation of Azobenzenoid Derivatives Against Trypanosomatid: RNA Editing Ligase 1 as a Potential Molecular Target. Acta Parasitologica, 71(5), Article 201. https://doi.org/10.1007/s11686-026-01391-1

Image Credits: AI Generated

DOI: 10.1007/s11686-026-01391-1

Keywords: Trypanosoma cruzi, Leishmania amazonensis, RNA editing ligase 1, azobenzenoid derivatives, Chagas disease, leishmaniasis, molecular docking, molecular dynamics simulation, drug discovery, neglected tropical diseases, cytotoxicity, CaCS2

The research team led by Jamdhade et al. embarked on an extensive biochemical and structural exploration of this enzyme, which belongs to the widespread NUDIX hydrolase superfamily. Members of this family are known for catalyzing the hydrolysis of nucleoside diphosphates linked to various moieties, playing crucial roles in cellular housekeeping, RNA metabolism, and the maintenance of nucleotide pool fidelity. However, the selective functions and nuances of NUDIX enzymes in parasitic protozoa have remained largely uncharted until now.

Using advanced cloning and recombinant protein expression techniques, the investigators successfully isolated the gene encoding the Leishmania major NUDIX hydrolase and expressed it in bacterial systems. Subsequent purification and enzymatic assays confirmed its activity profile and substrate specificity, revealing a distinctive preference for particular nucleotide diphosphate derivatives. This substrate activity pattern adds a new layer of understanding about how the parasite modulates nucleotide metabolism to counter oxidative stress and DNA damage during infection.

Structurally, the enzyme exhibits conserved motifs characteristic of the NUDIX family, including the signature NUDIX box—a sequence crucial for coordinating metal ions necessary for catalysis. Through site-directed mutagenesis, the researchers identified key amino acid residues that govern enzymatic activity and stability, providing insight into the molecular architecture that controls the enzyme’s function. Such detailed mapping paves the way for rational drug design aimed at disrupting enzyme activity selectively in the parasite.

The team further explored kinetic parameters of the enzyme, such as Km and Vmax, under varying pH and temperature conditions mimicking the intracellular environment of the host macrophage. Notably, the enzyme demonstrated remarkable stability and efficiency at physiological temperatures and appeared optimized for operation within the oxidative milieu of the parasitophorous vacuole. This adaptive functionality underscores the parasite’s evolutionary fine-tuning of enzymatic systems to thrive within hostile host compartments.

By investigating the enzyme’s response to potential inhibitors and metal cofactors, the study highlighted possible regulatory mechanisms that could be exploited for therapeutic targeting. Certain divalent cations enhanced or suppressed enzymatic activity, suggesting that chelation strategies or small molecules mimicking substrate analogs might serve as potent inhibitors. This aspect is particularly exciting given that current treatments for leishmaniasis suffer from toxicity and increasing resistance, illustrating the urgent need for novel drug targets.

The biological role of NUDIX hydrolase in Leishmania major appears multi-faceted. Besides its canonical function in nucleotide metabolism, the enzyme may contribute to controlling reactive oxygen species (ROS) levels and nucleic acid integrity, vital for parasite survival within immune cells generating oxidative bursts. The study hypothesizes that disruption of NUDIX hydrolase activity could tip the balance toward parasite clearance by undermining its ability to mitigate oxidative damage.

Moreover, comparative analyses with NUDIX hydrolases from other protozoan species revealed evolutionary conservation intertwined with species-specific adaptations. These findings hint at a conserved mechanism by which protozoan parasites safeguard their metabolic and genetic machinery, yet with subtle variations that could be harnessed to develop species-selective inhibitors, minimizing host toxicity.

The elucidation of the NUDIX hydrolase structure-function relationship also reveals clues about potential interactions with other parasite proteins involved in nucleotide metabolism and DNA repair pathways. The interplay between these molecular systems may form a coordinated network sustaining parasite viability under stress, an area ripe for future investigation with implications for disrupting parasite life cycles.

Aside from therapeutic prospects, this research enriches the broader field of enzymology and parasitology by demonstrating how parasites adapt ubiquitous enzymatic families for specialized functions suited to their unique intracellular niches. It underscores the importance of studying parasite-specific enzyme isoforms to understand pathogen biology deeply and uncover novel vulnerabilities.

Overall, the work presented by Jamdhade and colleagues exemplifies a meticulous fusion of molecular biology, biochemistry, and structural analysis, charting uncharted territory in parasite enzymology. The insights gleaned hold promise not only for advancing leishmaniasis research but also for inspiring new strategies against other kinetoplastid parasites, such as Trypanosoma species, sharing similar enzymatic pathways.

As the global burden of leishmaniasis persists, predominantly afflicting impoverished populations in tropical and subtropical regions, the discovery of druggable targets like NUDIX hydrolase offers a hopeful vision for more effective, less toxic interventions. Future research building on this foundation may lead to innovative therapies that can alleviate suffering and halt disease progression more efficiently than current options.

The study’s achievement also provides a template for exploring other understudied enzymes within parasites, emphasizing a paradigm shift toward integrative biochemical characterization to complement genomic and proteomic data. Such holistic approaches are critical for unraveling the complex web of interactions sustaining parasitic diseases.

In essence, the characterization of Leishmania major’s NUDIX hydrolase is more than a mere enzymatic profile; it is a strategic step in the global scientific endeavor to decode the molecular secrets of parasitism. By dissecting the enzyme’s mechanistic features, researchers have illuminated a potential Achilles’ heel in the parasite’s armor, inviting the scientific community to exploit this vulnerability.

This landmark study will undoubtedly influence subsequent research pathways and drug discovery programs, stimulating renewed interest in the enzymatic machinery of protozoan parasites. The challenge now lies in translating these molecular insights into tangible therapies, a journey that this pioneering work has significantly propelled.

As we await further developments, this detailed enzyme characterization serves as a testament to the power of fundamental biochemical research in addressing pressing global health challenges and advancing the frontiers of parasitology.

Subject of Research: Characterization of NUDIX hydrolase enzyme from Leishmania major

Article Title: Characterization of NUDIX hydrolase from Leishmania major

Article References:
Jamdhade, M.D., Shivalingappa, P.K.M., Atre, A.N. et al. Characterization of NUDIX hydrolase from Leishmania major. Acta Parasit. 70, 124 (2025). https://doi.org/10.1007/s11686-025-01065-4

Image Credits: AI Generated